Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Surgical treatment for neuroendocrine liver metastasis: moving ahead in controversy.

Literature DB >> 35004957

Surgical treatment for neuroendocrine liver metastasis: moving ahead in controversy.

Jun-Xi Xiang¹, Yi Lv¹, Xu-Feng Zhang¹.

Abstract

Entities: Chemical

Year: 2021 PMID： 35004957 PMCID： PMC8683918 DOI： 10.21037/hbsn-21-360

Source DB: PubMed Journal: Hepatobiliary Surg Nutr ISSN： 2304-3881 Impact factor: 7.293

× No keyword cloud information.

15 in total

Review 1. New and emerging systemic therapy options for well-differentiated gastroenteropancreatic neuroendocrine tumors.

Authors: Steven D Scoville; Jordan M Cloyd; Timothy M Pawlik
Journal: Expert Opin Pharmacother Date: 2019-11-24 Impact factor: 3.889

Review 2. Recommendations for management of patients with neuroendocrine liver metastases.

Authors: Andrea Frilling; Irvin M Modlin; Mark Kidd; Christopher Russell; Stefan Breitenstein; Riad Salem; Dik Kwekkeboom; Wan-yee Lau; Catherine Klersy; Valerie Vilgrain; Brian Davidson; Mark Siegler; Martyn Caplin; Enrico Solcia; Richard Schilsky
Journal: Lancet Oncol Date: 2014-01 Impact factor: 41.316

3. Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?

Authors: Jun-Xi Xiang; Xu-Feng Zhang; Eliza W Beal; Matthew Weiss; Luca Aldrighetti; George A Poultsides; Todd W Bauer; Ryan C Fields; Shishir Kumar Maithel; Hugo P Marques; Timothy M Pawlik
Journal: Ann Surg Oncol Date: 2018-09-14 Impact factor: 5.344

4. Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis.

Authors: Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Ioannis D Kostakis; Demetrios Moris; Dimitrios Schizas; Jordan M Cloyd; Timothy M Pawlik
Journal: J Gastrointest Surg Date: 2019-01-22 Impact factor: 3.452

Review 5. Therapeutic strategies for neuroendocrine liver metastases.

Authors: Andrea Frilling; Ashley K Clift
Journal: Cancer Date: 2014-10-01 Impact factor: 6.860

Review 6. Neuroendocrine liver metastases: a contemporary review of treatment strategies.

Authors: Jordan M Cloyd; Aslam Ejaz; Bhavana Konda; Mina S Makary; Timothy M Pawlik
Journal: Hepatobiliary Surg Nutr Date: 2020-08 Impact factor: 7.293

7. Management and outcomes of patients with recurrent neuroendocrine liver metastasis after curative surgery: An international multi-institutional analysis.

Authors: Gaya Spolverato; Fabio Bagante; Luca Aldrighetti; George A Poultsides; Todd W Bauer; Ryan C Fields; Shishir Kumar Maithel; Hugo P Marques; Matthew Weiss; Timothy M Pawlik
Journal: J Surg Oncol Date: 2017-05-17 Impact factor: 3.454

1. Highly variable biodistribution of ⁶⁸Ga labeled somatostatin analogues ⁶⁸Ga-DOTA-NOC and ⁶⁸Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT.

Authors: Monica Cheng; Mark Tann
Journal: Hepatobiliary Surg Nutr Date: 2022-10 Impact factor: 8.265

1 in total

Surgical treatment for neuroendocrine liver metastasis: moving ahead in controversy.

Review 1. New and emerging systemic therapy options for well-differentiated gastroenteropancreatic neuroendocrine tumors.

Review 2. Recommendations for management of patients with neuroendocrine liver metastases.

3. Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?

4. Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis.

Review 5. Therapeutic strategies for neuroendocrine liver metastases.

Review 6. Neuroendocrine liver metastases: a contemporary review of treatment strategies.

7. Management and outcomes of patients with recurrent neuroendocrine liver metastasis after curative surgery: An international multi-institutional analysis.

8. The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors.

9. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors.

Review 10. Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?

1. Highly variable biodistribution of ⁶⁸Ga labeled somatostatin analogues ⁶⁸Ga-DOTA-NOC and ⁶⁸Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT.

Surgical treatment for neuroendocrine liver metastasis: moving ahead in controversy.

Review 1. New and emerging systemic therapy options for well-differentiated gastroenteropancreatic neuroendocrine tumors.

Review 2. Recommendations for management of patients with neuroendocrine liver metastases.

3. Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?

4. Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis.

Review 5. Therapeutic strategies for neuroendocrine liver metastases.

Review 6. Neuroendocrine liver metastases: a contemporary review of treatment strategies.

7. Management and outcomes of patients with recurrent neuroendocrine liver metastasis after curative surgery: An international multi-institutional analysis.

8. The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors.

9. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors.

Review 10. Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?

1. Highly variable biodistribution of 68Ga labeled somatostatin analogues 68Ga-DOTA-NOC and 68Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT.

1. Highly variable biodistribution of ⁶⁸Ga labeled somatostatin analogues ⁶⁸Ga-DOTA-NOC and ⁶⁸Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT.